RG 7775

Drug Profile

RG 7775

Alternative Names: RG7775; RO 6839921

Latest Information Update: 01 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto-oncogene protein c mdm2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Solid tumours

Most Recent Events

  • 30 Oct 2017 Efficacy, adverse event and pharmacokinetic data from a phase I study in Solid tumours were presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
  • 27 Dec 2016 Interim efficacy, adverse event and pharmacokinetic data from a phase I study in Solid tumour were presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016)
  • 01 Nov 2016 Roche completes enrolment in its phase I trial for Solid tumour in USA and Canada (NCT02098967)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top